More than half of patients with chronic lymphocytic leukemia (CLL) who received ibrutinib for more than 3 years and had residual clonal lymphocytosis were found through next-generation sequencing to have a BTK mutation, and presence of this mutation was associated with subsequent disease progression, according to data from a FILO group study.1

“Mutational
analyses performed following acquired ibrutinib resistance have suggested that
CLL progression on ibrutinib is linked to mutations in the Bruton’s tyrosine
kinase (BTK) and/or phospholipase
Cg2 (PLCG2) genes,”
researchers wrote. “However, mutational information for patients still on
ibrutinib, without evidence of CLL progression, is limited.”

Related Articles

Therefore,
in this study, researchers wanted to evaluate a group of real-life patients
being treated with ibrutinib as part of an early-access program launched in
2014 that allowed for prolonged use of the drug.

Of
204 patients across 29 French Innovative Leukemia Organization (FILO) centers who
were enrolled in the early-access program, 31% (63 patients) were still on
ibrutinib after 3 years and were able to provide a fresh blood sample.

Of
the 63 patients, 30 had a CLL clone of 0.5 x 109/L or greater and
were able to undergo next-generation sequencing. At least one BTK
mutation was present in 57% of samples, and PLCG2 mutations were found
in 13% of samples.

With
a median follow-up of 8.5 months from sample collection, those patients with a BTK
mutation has significantly higher risk for CLL progression compared with
patients who had no mutation (P =.0005).

“Our
findings support that mutational analyses should be considered in patients
receiving ibrutinib who have residual clonal lymphocytosis, and that clinical
trials are needed to evaluate whether patients with a BTK mutation may
benefit from an early switch to another treatment,” the researchers wrote.

Reference

Quinquenel A, Fornecker LM, Letestu R, et al. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after three years: FILO group study. [published online June 26, 2019]. Blood. doi: 10.1182/blood.2019000854

This article originally appeared on Cancer Therapy Advisor